Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, comments on the logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma (NHL), highlighting the need for optimized patient referral, efficient approval processes, and shorter manufacturing times. Prof. Sureda emphasizes the importance of ensuring patients have a good performance status and disease control before undergoing CAR-T therapy and notes that a significant proportion of patients (50-55%) ultimately do not receive the treatment due to having to wait four to six weeks for infusion after being identified as a potential candidate for CAR-T. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть